For our loyal followers, you may have noticed we skipped a beat. Sorry about that – we’ve been busy little bees in our Seattle beehive. But our absence means good things for you and your research. See our latest newsletter for your first glimpse at our quickly growing collection of immunological services. Are you interested in cytokines and their regulation […]
Subscribing members should be receiving our latest “Tools and Views” early next week. This issue introduces our new KinoCore services – more information is just a click away!
Subscribing members should be receiving our latest “Tools and Views” this week. This issue explores allosteric inhibitors and their impact on combating therapeutic resistance due to somatic mutations. Like what you see? Then you might also like this slightly older publication by Yong Jia and colleagues. Remember, many of these mutations have no effect on biochemical binding – but they […]
We’re launching a new series that we call “Real Science Facts”. Our first new article in this series explores what has been published regarding long-term compound stability. Ever wonder just how long you can keep that new compound in you bench drawer? We explore the answer to that question in more depth – just click here.
Subscribing members should be receiving our latest “Tools and Views” this week. This issue explores some of the research services available to our current and prospective clientele. Now you can take a summer break and still get your work done! Check out the T & V archive to review this and past issues.
We are pleased to announce the launch our new “Interleukin Activity Profiling Service.” This marks our first departure from kinase activity profiling services, and our eventual expansion of services and products targeting the industry’s growing interest in immuno-oncology. To learn more, please drop down the “Services” menu on our header banner above. Be sure to check back frequently to stay up-to-date […]
Enjoyed reading the latest publication from Novartis on ABL001 – a direct descendant of the GNF-2 and GNF-5 allosteric ABL inhibitors (https://www.nature.com/nature/journal/v543/n7647/full/nature21702.html). This class of compounds binds to the myristoyl binding pocket to disrupt kinase function. Intriguing aside were the effects that ABL001 had on the activity of ATP mimetics including Imatinib and Nilotinib (you may know the former as Gleevec). […]
We returned recently from the annual SLAS convention held in Washington DC. We presented a poster evaluating the influence of the cellular environment on small-molecule efficacy. For those of you that were unable to attend, please click the image below to view the poster handout:
We’ve been busy and it’s with great pride that we roll out our 100th cell-based protein tyrosine kinase assay. At the same time we’re also performing an overhaul of the website, so please forgive the mess during construction. You’ll notice some new twists and turns with the panel; for some the rationale is obvious, but for others – such as […]
ACD was incorporated in 2007 and we have slowly been building our presence in the kinase drug discovery industry. Our clients include most of the major pharmaceutical and biotechnology leaders in the kinase field. Our growing presence in the industry has – unfortunately – not been reflected in our website presence. That is all about to change! On this site you will discover a host of new tools that will give you easier access to information about who we are, what we offer, and how we can better help your kinase drug discovery efforts. Please take a few moments to register and learn more about our panel of sixty-nine (69) cell-based tyrosine kinase assays.